MedTrace Logo

Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

NCT03971279 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2019-11-26

No results posted yet for this study

Summary

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Conditions

  • Posterior Uveitis

Interventions

DRUG

Dexamethasone Ophthalmic implant

intravitreal injection of ozurdex implant

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Tarek Elhamaky · Benha university faculty of medicine , INMC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-11-22
Completion
2019-11-22

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03971279 on ClinicalTrials.gov